Clinical Trial Update: Effect of Single Doses of 10 mg NRL001 Applied as a Suppository to the Anal Canal or Rectum [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating single 10 mg doses of NRL001 as a suppository to the anal canal or rectum for fecal incontinence; the study has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fecal Incontinence

Drugs mentioned

• NRL001

Snippet

Sponsor: Norgine | Conditions: Fecal Incontinence | Phase 1 | Status: COMPLETED